53 related articles for article (PubMed ID: 9516940)
21. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
22. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
23. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
24. In vivo/ex vivo and in situ assays used in cancer research: a brief review.
Teicher BA
Toxicol Pathol; 2009 Jan; 37(1):114-22. PubMed ID: 19098118
[TBL] [Abstract][Full Text] [Related]
25. The effect of chemotherapeutic agents on wound healing.
Shamberger RC; Devereux DF; Brennan MF
Int Adv Surg Oncol; 1981; 4():15-58. PubMed ID: 6788710
[TBL] [Abstract][Full Text] [Related]
26. [Diurnal variations in the response of cells to factors altering mitotic activity].
Alov IA
Usp Sovrem Biol; 1978; 86(2):216-26. PubMed ID: 364862
[No Abstract] [Full Text] [Related]
27. High-dose chemotherapy regimens for solid tumors.
van der Wall E; Beijnen JH; Rodenhuis S
Cancer Treat Rev; 1995 Mar; 21(2):105-32. PubMed ID: 7758003
[TBL] [Abstract][Full Text] [Related]
28. [High-dose chemotherapy: principles, indications and complications].
Göbel U; Jürgens H; Schwamborn D; Wahn V
Klin Padiatr; 1988; 200(1):1-6. PubMed ID: 3285085
[TBL] [Abstract][Full Text] [Related]
29. Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy.
Dray S; Mokyr MB
Med Oncol Tumor Pharmacother; 1989; 6(1):77-85. PubMed ID: 2657252
[TBL] [Abstract][Full Text] [Related]
30. [Intensification of cytostatic action by radiosensitizers--a review of the present status of chemosensitization].
Moldenhauer H; Rose H; Saul G; Wolf G; Kehrberg G
Radiobiol Radiother (Berl); 1984; 25(2):289-95. PubMed ID: 6234615
[No Abstract] [Full Text] [Related]
31. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors.
St Croix B; Man S; Kerbel RS
Cancer Lett; 1998 Sep; 131(1):35-44. PubMed ID: 9839618
[TBL] [Abstract][Full Text] [Related]
32. Patterns of resistance and therapeutic synergism among alkylating agents.
Schabel FM; Trader MW; Laster WR; Wheeler GP; Witt MH
Antibiot Chemother (1971); 1978; 23():200-15. PubMed ID: 348078
[TBL] [Abstract][Full Text] [Related]
33. Tumor inhibitory properties of anaerobic Corynebacteria.
Woodruff MF
Transplant Proc; 1975 Jun; 7(2):229-32. PubMed ID: 1093294
[No Abstract] [Full Text] [Related]
34. Cancer chemotherapy. I.
Greenwald ES
N Y State J Med; 1972 Oct; 72(20):2541-56. PubMed ID: 4627868
[No Abstract] [Full Text] [Related]
35. Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity.
Ben-Efraim S
Curr Drug Targets; 2001 Jun; 2(2):197-212. PubMed ID: 11469719
[TBL] [Abstract][Full Text] [Related]
36. The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours.
Porrata LF; Adjei AA
Br J Cancer; 2001 Aug; 85(4):484-9. PubMed ID: 11506483
[TBL] [Abstract][Full Text] [Related]
37. Hexamethylene bisacetamide: a polar-planar compound entering clinical trials as a differentiating agent.
Chun HG; Leyland-Jones B; Hoth D; Shoemaker D; Wolpert-DeFilippes M; Grieshaber C; Cradock J; Davignon P; Moon R; Rifkind R
Cancer Treat Rep; 1986 Aug; 70(8):991-6. PubMed ID: 3524838
[No Abstract] [Full Text] [Related]
38. [Alkylating cytostatic agents].
Schmidt CG
Internist (Berl); 1971; 12():Suppl 1:119-27. PubMed ID: 5002874
[No Abstract] [Full Text] [Related]
39. [Adaptation of the body to alkylating anti-tumor substances].
Kulik GI; Pel'kis FP; Korol' VI
Eksp Onkol; 1989; 11(6):34-8. PubMed ID: 2510987
[TBL] [Abstract][Full Text] [Related]
40. Intensive chemotherapy for solid tumours--current clinical applications.
Kaye SB
Cancer Chemother Pharmacol; 1982; 9(3):127-33. PubMed ID: 6761009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
